A miracle occured! Fundraising for Artyom Sarmashov is closed

On Old New Year, a real miracle happened: fundraising for treatment of one of our wards, Artem Sarmashov from Volgograd, was closed.

In October 2020, Ekaterina and Vadim learned about a terrible disease of their half-year-old son - type II spinal muscular atrophy (SMA-2). Only the most expensive drug in the world, Zolgensma, could save the baby's life, the total cost of which is more than $ 2 million.

Artyom's parents started fundraising. Employees of the E100 holding and the company's clients actively supported the charitable initiative to help a little boy with SMA. The missing amount was closed by one of the patrons who wished to remain incognito.

The E100 Family project wishes Artem a rapid recovery and thanks everyone who did not just stand aside and contributed to saving the boy's life.

We believe in miracles and that there should be as many of them as possible!

Request for financial assistance for E100 drivers and their families
Details

I consent to the processing by E100 International Trade Sp. z o.o. my personal data in the form of an e-mail address for the purpose of sending me marketing information regarding products and services offered by E100 International Trade Sp. z o.o. by means of electronic communication, pursuant to the provisions of art. 10 sec. 1 and 2 of the Act on the provision of electronic services. Detailed rules regarding the processing of personal data and marketing consents are set out in the information clause. Before giving marketing consent, please read its content.

Details

I consent to the processing of my personal data in the form of the telephone number provided by me by E100 International Trade Sp. z o.o. in order to conduct marketing activities with the use of telecommunications terminal equipment and automatic calling systems within the meaning of the Telecommunications Law. Detailed rules regarding the processing of personal data and marketing consents are set out in the information clause. Before giving marketing consent, please read its content.